EVLO Insider Trading
Insider Ownership Percentage: 1.02%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Evelo Biosciences Share Price & Price History
Current Price: $0.00
Price Change: ▲ Price Increase of +0.0004 (400.00%)
As of 12/19/2025 03:46 PM ET
Evelo Biosciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/8/2023 | Marella Thorell | CFO | Sell | 1,811 | $0.33 | $597.63 | 22,259 |  |
| 11/8/2023 | Mark Bodmer | Insider | Sell | 3,163 | $0.33 | $1,043.79 | 25,732 | |
| 11/8/2023 | Simba Gill | CEO | Sell | 172 | $0.33 | $56.76 | 17,758 | |
| 9/28/2023 | Simba Gill | CEO | Sell | 1,996 | $3.94 | $7,864.24 | 16,758 | |
| 8/8/2023 | Marella Thorell | CFO | Sell | 2,004 | $9.51 | $19,058.04 | 9,069 | |
| 8/8/2023 | Mark Bodmer | Insider | Sell | 3,128 | $9.51 | $29,747.28 | 16,624 | |
| 8/8/2023 | Simba Gill | CEO | Sell | 342 | $9.51 | $3,252.42 | 3,754 | |
| 7/11/2023 | Ventures Fund Iv Gene Flagship | Major Shareholder | Buy | 5,411,255 | $2.31 | $12,499,999.05 | 3,931,685 | |
| 5/23/2023 | Mark Bodmer | Insider | Sell | 1,128 | $2.80 | $3,158.40 | 13,127 | |
| 5/8/2023 | Duncan Mchale | Insider | Sell | 3,336 | $2.60 | $8,673.60 | 4,875 | |
| 5/8/2023 | Marella Thorell | CFO | Sell | 1,926 | $2.60 | $5,007.60 | 4,573 | |
| 5/8/2023 | Simba Gill | CEO | Sell | 176 | $2.60 | $457.60 | 2,925 | |
| 1/23/2023 | Stephen J Carriere | Insider | Sell | 7 | $21.20 | $148.40 | 10 | |
Evelo Biosciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 1/1/2024 | Vanguard Group Inc. | 357,711 | $1.40M | 0.0% | +129.5% | 1.885% |  |
| 11/13/2023 | FMR LLC | 2,446,390 | $9.59M | 0.0% | +1,835.1% | 12.923% | |
| 11/7/2023 | Barclays PLC | 11,755 | $46K | 0.0% | -87.4% | 0.062% | |
| 8/9/2023 | Mayo Clinic | 22,577 | $73K | 0.1% | -95.3% | 0.403% | |
| 8/4/2023 | Alphabet Inc. | 53,024 | $0.17M | 0.0% | -95.0% | 0.947% | |
| 7/26/2023 | State of Michigan Retirement System | 203,536 | $0.66M | 0.0% | -95.0% | 3.635% | |
| 2/14/2023 | 683 Capital Management LLC | 90,291 | $0.15M | 0.0% | N/A | 0.084% | |
| 2/9/2023 | Mayo Clinic | 479,242 | $0.77M | 0.4% | N/A | 0.444% | |
| 1/26/2023 | Mayo Clinic | 479,242 | $0.77M | 3.9% | N/A | 0.444% | |
| 11/16/2022 | Alphabet Inc. | 1,060,495 | $2.22M | 0.1% | N/A | 0.982% | |
| 11/14/2022 | Ergoteles LLC | 27,429 | $57K | 0.0% | -91.0% | 0.025% | |
| 8/16/2022 | CVI Holdings LLC | 2,054,794 | $4.34M | 0.3% | N/A | 3.829% | |
| 8/15/2022 | Flagship Pioneering Inc. | 50,427,328 | $106.40M | 4.0% | +119.0% | 93.976% | |
| 8/12/2022 | FMR LLC | 16,185,709 | $34.15M | 0.0% | +101.2% | 30.163% | |
| 8/8/2022 | State of Michigan Retirement System | 4,070,728 | $8.59M | 0.1% | +270.1% | 7.586% | |
| 8/5/2022 | abrdn plc | 342,465 | $0.72M | 0.0% | N/A | 0.638% | |
| 8/3/2022 | AE Wealth Management LLC | 56,029 | $0.12M | 0.0% | +78.2% | 0.104% | |
| 5/12/2022 | Group One Trading L.P. | 452,939 | $1.54M | 0.0% | +93.4% | 0.844% | |
| 5/11/2022 | GSA Capital Partners LLP | 72,871 | $0.25M | 0.0% | N/A | 0.136% | |
| 4/20/2022 | Belvedere Trading LLC | 172,792 | $0.40M | 0.0% | -28.3% | 0.322% | |
| 4/18/2022 | AE Wealth Management LLC | 31,437 | $0.11M | 0.0% | +61.0% | 0.059% | |
| 2/14/2022 | Virtus ETF Advisers LLC | 22,257 | $0.14M | 0.1% | +71.1% | 0.042% | |
| 2/14/2022 | Credit Suisse AG | 3,566,487 | $21.65M | 0.0% | +7.7% | 6.671% | |
| 2/11/2022 | Alberta Investment Management Corp | 40,000 | $0.24M | 0.0% | N/A | 0.075% | |
| 2/8/2022 | ProShare Advisors LLC | 14,162 | $86K | 0.0% | N/A | 0.026% | |
| 2/8/2022 | Northern Trust Corp | 300,436 | $1.82M | 0.0% | +0.8% | 0.562% | |
| 2/3/2022 | Larson Financial Group LLC | 5,879 | $36K | 0.0% | -80.2% | 0.011% | |
| 2/2/2022 | New York State Common Retirement Fund | 15,765 | $96K | 0.0% | +57.8% | 0.029% | |
| 1/25/2022 | Belvedere Trading LLC | 241,137 | $1.18M | 0.1% | +75.1% | 0.451% | |
| 1/20/2022 | AE Wealth Management LLC | 19,528 | $0.12M | 0.0% | +21.5% | 0.037% | |
| 11/16/2021 | Two Sigma Advisers LP | 140,600 | $0.99M | 0.0% | +16.7% | 0.263% | |
| 11/15/2021 | Marshall Wace LLP | 38,807 | $0.27M | 0.0% | -38.0% | 0.073% | |
| 11/15/2021 | GSA Capital Partners LLP | 11,624 | $82K | 0.0% | N/A | 0.022% | |
| 11/12/2021 | The Manufacturers Life Insurance Company | 10,483 | $74K | 0.0% | -43.5% | 0.020% | |
| 11/12/2021 | Credit Suisse AG | 3,310,911 | $23.31M | 0.0% | +7.0% | 6.193% | |
| 11/12/2021 | Geode Capital Management LLC | 520,717 | $3.67M | 0.0% | +10.3% | 0.974% | |
| 11/10/2021 | Goldman Sachs Group Inc. | 38,492 | $0.27M | 0.0% | +43.7% | 0.072% | |
| 11/10/2021 | Citigroup Inc. | 5,742 | $40K | 0.0% | +297.6% | 0.011% | |
| 11/9/2021 | Barclays PLC | 12,412 | $87K | 0.0% | +223.0% | 0.023% | |
| 11/9/2021 | BlackRock Inc. | 1,840,250 | $12.95M | 0.0% | -0.2% | 3.442% | |
| 11/8/2021 | State Board of Administration of Florida Retirement System | 10,241 | $72K | 0.0% | N/A | 0.019% | |
| 11/8/2021 | Meeder Asset Management Inc. | 8,858 | $61K | 0.0% | +82.4% | 0.017% | |
| 11/4/2021 | Deutsche Bank AG | 36,952 | $0.26M | 0.0% | +81.8% | 0.069% | |
| 11/4/2021 | Larson Financial Group LLC | 29,705 | $0.21M | 0.0% | -5.3% | 0.056% | |
| 11/2/2021 | New York State Common Retirement Fund | 9,988 | $70K | 0.0% | -63.4% | 0.019% | |
| 11/1/2021 | AE Wealth Management LLC | 16,077 | $0.11M | 0.0% | +14.1% | 0.030% | |
| 11/1/2021 | SG Americas Securities LLC | 10,454 | $74K | 0.0% | N/A | 0.020% | |
| 9/3/2021 | Parametric Portfolio Associates LLC | 22,216 | $0.31M | 0.0% | -21.3% | 0.042% | |
Data available starting January 2016
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More on Evelo Biosciences
Volume
875 shs
Average Volume
9,105 shs
Market Capitalization
$9.42 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.68
